HBM Holdings Partner Doses First Patient in SKB378 COPD Study

MT Newswires Live

06/10

HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.

The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.

The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.

In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.

The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2642410373"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642410373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642410373?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642410373","market":"nz","top_or_hot":-1,"title":"HBM Holdings Partner Doses First Patient in SKB378 COPD Study","media":"MT Newswires Live","content":"<html><body><p> HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.</p><p>The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.</p><p>The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.</p><p>In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.</p><p>The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Partner Doses First Patient in SKB378 COPD Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Partner Doses First Patient in SKB378 COPD Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-10 13:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.</p><p>The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.</p><p>The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.</p><p>In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.</p><p>The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642410373","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642410373","pubTimestamp":1781070453,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HBM Holdings  said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","02142":"和铂医药-B","BK1161":"生物科技","BK4588":"碎股","DRAM":"Roundhill Memory ETF","BK1574":"生物医药B类股"},"translate_title":"HBM Holdings合作伙伴为SKB378 COPD研究中的首例患者进行给药","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/eb223e33d40a2eb3e7ccb9dd56904804","symbols_score_info":{"DRAM":1.5,"02142":1},"content_text":"HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}